1. Nurnberg HG, Hensley PL, Heiman JR, et al. Sildenafil treatment of women with antidepressant-associated sexual dysfunction: a randomized controlled trial. JAMA. 2008;300:395-404.
2. Physicians’ Desk Reference. 62nd ed. Montvale, NJ: Thomson Healthcare, Inc.; 2007.
3. Food, Drug and Cosmetic Act, 21USC §396
4. Richardson v Miller. 44 SW3d 1 (Tenn Ct App 2000).
5. Buckman Co. v Plaintiffs’ Legal Comm., 531 US 341 (2001).
6. Bridge JA, Iyengar S, Salary CB, et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA. 2007;297:1683-1696.
7. Baldwin DS, Kosky N. Off-label prescribing in psychiatric practice. Adv Psychiatr Treat. 2007;13:414-422.
8. Conroy S, Choonara I, Impicciatore P, et al. Survey of unlicensed and off label drug use in paediatric wards in European countries. European Network for Drug Investigation in Children. BMJ. 2000;320:79-82.
9. Radley DC, Finkelstein SN, Stafford RS. Off-label prescribing among office-based physicians. Arch Intern Med. 2006;166:1021-1026.
10. Mehlman MJ. Off-label prescribing. Available at: http://www.thedoctorwillseeyounow.com/articles/bioethics/offlabel_11. Accessed October 21, 2008.
11. Connolly H, Crary J, McGoon M, et al. Vascular heart disease associated with fenfluramine-phentermine. N Engl J Med. 1997;337:581-588.
12. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA. 2004;291:1701-1712.
13. Sismondo S. Ghost management: how much of the medical literature is shaped behind the scenes by the pharmaceutical industry? PLoS Med. 2007;4(9):e286.-
14. Steinman MA, Bero L, Chren M, Landefeld CS. Narrative review: the promotion of gabapentin: an analysis of internal industry documents. Ann Intern Med. 2006;145:284-293.
15. Gøtzsche PC, Hróbjartsson A, Johansen H, et al. Ghost authorship in industry-initiated randomised trials. PLoS Med. 2007;4(1):e19.-
16. Smith R. Medical journals are an extension of the marketing arm of pharmaceutical companies. PLoS Med. 2005;2(5):e138.-
17. Horton R. The dawn of McScience. New York Rev Books. 2004;51(4):7-9.
18. Turner EH, Matthews A, Linardatos E, et al. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med. 2008;358:252-260.
19. Henry V. Off-label prescribing. Legal implications. J Leg Med. 1999;20:365-383.
20. Klein v Biscup. 673 NE2d 225 (Ohio App 1996).
21. Beck JM, Azari ED. FDA, off-label use, and informed consent: debunking myths and misconceptions. Food Drug Law J. 1998;53:71-104.
22. Shajnfeld A, Krueger RB. Reforming (purportedly) non-punitive responses to sexual offending. Dev Mental Health Law. 2006;25:81-99.
